ArticleCirculation2022
Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?
Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.BMC medicine · 2025Trial
- Impact of Antihypertensive Drug Class on Outcomes in SPRINT.Hypertension (Dallas, Tex. : 1979) · 2022Trial
- Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trialsEuropean heart journal open · 2026Article
- Angiotensin-converting enzyme inhibitors show an edge over angiotensin II receptor blockers in cardiovascular outcomes.European heart journal open · 2026Article
- Adverse event of ACE inhibitors: A descriptive analysis of FAERS data.Journal of public health research · 2026Article
- General practitioners' perspectives, preferences, and practices in prescribing antihypertensive medication in primary, uncomplicated hypertension.Family practice · 2025Article
- Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study.Cardiovascular diabetology · 2025Article
- Angiotensin-Converting Enzyme Inhibition as a Potential Risk Factor for Periprosthetic Joint Infection Following Total Knee Arthroplasty.Arthroplasty today · 2025Article
- New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT.Journal of the American Heart Association · 2023Article
- ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights.Current hypertension reports · 2023Review
- Chemical Synthesis, Safety and Efficacy of Antihypertensive Candidate Drug 221s (2,9).Molecules (Basel, Switzerland) · 2023Article
- Decreased risk of radiation pneumonitis with concurrent use of renin-angiotensin system inhibitors in thoracic radiation therapy of lung cancer.Frontiers in medicine · 2023Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35130055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.